Related applications of Deferiprone(cas: 30652-11-0)

Product Manager: Selina Zhang; Email: selina@coreychem.com

Deferiprone (CAS: 30652-11-0) is a highly valuable orally active iron-chelating agent widely used in medicinal chemistry, clinical pharmacology, and analytical toxicology. Featuring a 3-hydroxy-1,2-dimethylpyridin-4-one (hydroxypyridinone) core, it offers exceptional selectivity for ferric iron (Fe³⁺), excellent oral bioavailability, and the unique ability to cross the blood‑brain barrier, making it an important therapeutic and research tool in modern medicine. The compound is primarily employed as an oral iron chelator for the treatment of transfusional iron overload in patients with thalassemia syndromes, sickle cell disease, and other anemias, with ongoing research exploring its potential in neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease. Its well-defined bidentate chelating structure, 3:1 (ligand:iron) binding stoichiometry, and reliable pharmacokinetic profile make it a dependable active pharmaceutical ingredient (API) for laboratory‑scale formulation development, analytical method validation, and routine clinical manufacturing. Its primary applications are outlined below:

1. Clinical Pharmacology & Iron Overload Therapy

Key Therapeutic Agent for Thalassemia and Transfusional Iron Overload

Deferiprone is an orally active iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease (SCD), or other anemias when current chelation therapy is inadequate. It was first approved in the European Union in 1999 and received U.S. FDA approval on October 14, 2011.

Mechanism of Action: Selective Fe³⁺ Chelation

As a bidentate chelator, deferiprone binds to ferric ions with high affinity (binding order at pH 7.4: Fe > Cu > Al > Zn), forming neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. The resulting red-colored iron-deferiprone complex is excreted primarily via urine, effectively removing excess iron from the body and preventing iron‑induced oxidative damage.

Clinical Efficacy and Safety

At oral doses of 75–100 mg/kg/day (typically 25–33 mg/kg three times daily), deferiprone effectively reduces serum ferritin levels and mobilizes iron from the liver and other storage organs, with efficacy comparable to the parenteral chelator deferoxamine. Over 600 patients across 26 centers have received deferiprone, in some cases daily for over 5 years, confirming its long‑term safety profile. The oral efficacy and lower cost make deferiprone more accessible than deferoxamine for the vast majority of patients requiring iron chelation worldwide.

⚠️ Safety Note: Deferiprone carries an FDA boxed warning for the risk of agranulocytosis and neutropenia. Absolute neutrophil count must be measured before starting therapy and monitored regularly while on treatment. The most common adverse events include neutropenia, abdominal pain, and red‑brown urine discoloration (from iron secretion).

2. Neuroscience Research & Neurodegenerative Disease

Brain‑Penetrant Iron Chelator for CNS Disorders

Deferiprone is an orally available, brain‑penetrant iron chelator that removes iron from the brain and other tissues. It is the only iron chelator with proven ability to cross the blood‑brain barrier, making it uniquely valuable for investigating iron‑related neurodegenerative mechanisms.

Alzheimer’s Disease Research

Excess brain iron correlates with accelerated cognitive decline in Alzheimer’s disease (AD). Deferiprone reduced cholesterol diet‑induced increases in amyloid‑β (Aβ42, Aβ40) levels, as well as tau phosphorylation and glycogen synthase kinase‑3β (GSK‑3β) phosphorylation in the rabbit hippocampus at a dose of 50 mg/kg. In rats treated with scopolamine, deferiprone lessened Aβ deposition and mitigated memory impairment. Deferiprone is currently in Phase 2 clinical trials for Alzheimer’s disease.

Parkinson’s Disease Research

Iron accumulation in specific brain regions contributes to the loss of dopamine‑producing nerve cells in Parkinson’s disease (PD). Deferiprone reversed ferroptosis induced by erastin in HT‑1080 fibrosarcoma cells at 100 μM and reduced intracellular iron levels in primary rat hepatocytes at 200 μM, while inhibiting lipid peroxidation at 50 μM. Deferiprone improved motor function in a mouse model of Huntington’s disease and behavioral deficits in a mouse model of α‑synuclein pathology. The drug is currently in Phase 2/3 clinical trials for Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

Ferroptosis Modulation

Deferiprone possesses antioxidant and neuroprotective activities, effectively reversing ferroptosis (iron‑dependent programmed cell death) induced by erastin in cancer cell models. It inhibits the Fenton reaction catalyzed by Fe²⁺ and Fe³⁺ ions, completely blocking hydroxyl radical production during light irradiation of iron aqua complexes, with no detectable formation of singlet oxygen or free oxygen radicals.

3. Advanced Intermediate & Functional Compound Development

Histone Demethylase Inhibition: Epigenetic Applications

Recent studies have revealed that deferiprone inhibits specific histone lysine demethylases (KDMs), which play critical roles in epigenetic regulation. At a concentration of 10 μM, deferiprone demonstrated over 95% inhibition of KDM6A, KDM2A, KDM2B, and KDM5C activities, while KDM1A (LSD1) was not affected. This discovery positions deferiprone as a valuable tool compound for cancer epigenetics research and potential repurposing in oncology.

Building Block for Novel Chelators and Metal‑Complexes

The 3‑hydroxy‑4‑pyridinone scaffold of deferiprone provides a versatile template for synthesizing novel α‑ketohydroxypyridine chelators with improved selectivity, pharmacokinetic properties, and metal‑binding profiles. The compound is also utilized in the development of controlled‑release pharmaceutical formulations using ultrasound‑assisted compression with thermoplastic polymers (e.g., Carbopol 974P and 971P), achieving sustained release with only 15% w/w excipient.

Impurity Reference Standards for Pharmaceutical QC

Deferiprone impurity reference standards are invaluable for pharmaceutical research, supporting product development, ANDA and DMF submissions, quality control (QC), method validation, and stability studies, with detailed Certificates of Analysis (COA) and analytical data meeting regulatory requirements.

4. Research & Development Applications

Analytical Method Development & Validation

Deferiprone serves as an analytical target for developing and validating various quantitative methods:

• RP‑HPLC: Validated ICH‑compliant methods for deferiprone estimation in pharmaceutical dosage forms using C18 columns (150 × 4.6 ID, 5 μm), mobile phase triethylamine buffer:acetonitrile (50:50 v/v), detection at 280 nm, retention time of approximately 4.9 minutes, linearity range 125–375 μg/mL (correlation coefficient 0.994), LOD 22.93 μg/mL, and LOQ 96.37 μg/mL.

• LC‑MS/MS and CE/FA: Highly sensitive methods for quantifying deferiprone and its iron(III) complex, with detection of nitrosamine impurities in deferiprone formulations at sub‑ppb levels.

• Advanced Analytical Platforms: Metal‑organic framework (MIL‑101/agarose)‑based nanocomposite hydrogels for fluorescence quantification of deferiprone in exhaled breath condensate, achieving an LOD of 0.003 μg/mL. Other reported techniques include spectrophotometry (LOD 0.012 μg/mL in exhaled breath condensate), flame atomic absorption spectroscopy (LOD 0.032 μg/mL), and LC‑MS/MS (LOD 0.05 μg/mL).

Process Development & Scale‑Up

As an FDA‑approved API (initial U.S. approval 2011, generic versions available), deferiprone has well‑established manufacturing routes, regulatory acceptance, and extensive clinical safety data. Its stable crystalline powder form (purity >98%) and well‑defined physicochemical properties make it suitable for laboratory‑scale synthesis, gram‑to‑kilogram API production for formulation studies, and process optimization for commercial oral tablet and solution dosage forms (available as 500 mg and 1,000 mg tablets, and 100 mg/mL oral solution). The recommended dosage is 25 mg/kg to 33 mg/kg body weight taken orally three times a day for a total daily dosage of 75 mg/kg to 100 mg/kg.

Cell Culture and In Vitro Studies

Deferiprone is widely employed in cell‑based assays to investigate iron homeostasis, oxidative stress, and ferroptosis. It protects myocytes from doxorubicin‑induced lactate dehydrogenase release at 100 μM, rapidly enters cells to displace iron from intracellular complexes, and greatly reduces hydroxyl radical production by iron‑doxorubicin complexes. Deferiprone also shows cytotoxic activity against human tumor cell lines HSC‑2, HSC‑3, and HL‑60 with IC₅₀ values of 13.5, 9.9, and 10.6 μg/mL, respectively, with cytotoxicity reduced in the presence of FeCl₃.

5. Handling & Storage

Storage Conditions

Store in tightly sealed, light‑protected containers under cool, dry conditions. Powder form is stable for up to 3 years at –20 °C and 2 years at 4 °C. Solutions should be stored at –80 °C for up to 6 months or at –20 °C for up to 1 month, with aliquotting recommended to avoid repeated freeze‑thaw cycles. Protect from moisture, strong oxidizing agents, and excessive light. Deferiprone and its Fe³⁺ complexes undergo rapid decomposition under UV light but are stable under visible light.

Intended Use

Deferiprone is intended for therapeutic use under medical supervision, pharmaceutical development, biochemical research, and analytical applications. It is not for direct over‑the‑counter use without appropriate medical oversight. For research purposes, it is classified as a small molecule drug with a maximum clinical trial phase of IV and has 5 approved and 12 investigational indications.

Summary

The value of deferiprone lies in its unique combination of a highly selective 3‑hydroxy‑4‑pyridinone iron‑chelating scaffold, oral bioavailability, and brain‑penetrant properties. This structure enables the effective removal of excess iron from the body in thalassemia and other transfusion‑dependent anemias, while also serving as a powerful research tool for investigating iron‑mediated neurodegeneration, ferroptosis, and epigenetic regulation via histone demethylase inhibition. Its established clinical safety, reliable chelation chemistry, and diverse applications from clinical therapy to analytical method development make it an indispensable API and research compound for modern pharmaceutical science, neurology, and analytical chemistry.

Contact us for more information: selina@coreychem.com